



## **KDA GROUP AND ZOOMMED JOIN FORCES TO DISTRIBUTE THE ZRX PRESCRIBER IN THE UNITED STATES**

**Thetford Mines, June 1<sup>st</sup>, 2018** - KDA Group Inc. (TSXV: KDA) ("**KDA Group**" or the "**Corporation**") is proud to announce an agreement with ZoomMed Inc. (TSXV: ZMD) ("**ZoomMed**") whereby KDA Group can distribute under a non-exclusive license the ZRx Prescriber developed by ZoomMed in the United States. The Corporation and ZoomMed are also expecting to conclude, shortly, a joint venture agreement in order to unite their expertise for the development and commercialization of the ZRx Prescriber in the US market. KDA Group and ZoomMed are arms' length parties.

KDA Group will issue ZoomMed 10,000,000 common class A shares of its share capital (the "**Common Shares**") at a deemed value of \$1,720,000 CAD, based on the average closing price of the Common Shares for the last 52 weeks to April 30<sup>th</sup>, 2018, being \$ 0.172 CAD per Common Share. In addition, ZoomMed will be entitled to receive royalties, up to US \$2,500,000 under certain terms and conditions. The Common Shares will be subject to a four month and one day mandatory holding period.

"This agreement will accelerate the growth of ZoomMed's healthcare solutions in the vast US market estimated at more than 800 million US dollars. The expertise of KDA Group's management and the team of its subsidiary pharmaceutical communication will definitely be an additional strategic key to our success," said Mr. Yves Marmet, President and CEO of ZoomMed.

"Our subsidiary's mission is to provide excellence at all times through the distribution of educational and communication programs in the medical field, from the development to the implementation of strategies offered to large pharmaceutical companies for the purpose of improving patients' health. Thanks to ZoomMed's technology platform, we will be able to expand our service offerings to physicians and patients in the US market," said Marc Lemieux, President and CEO of KDA Group.

"The e-prescribing market for 900,000 American physicians offers the perfect window of opportunity for the commercialization of ZoomMed's software solution and business model", added Mr. Lemieux.

The agreement and Common Shares issuance are subject to all required approvals including the final approval of the TSX Venture Exchange.

### **About KDA Group**

KDA Group is a leading solution and service provider to the pharmaceutical market for the distribution of generic drugs and specialized solutions. Today, it is a respected name for quality and expertise among pharmacists. Its management team is guided by a vision of continuing to lead the way in Quebec while extending operations across Canada and internationally. Additional information on the Corporation is available at [www.kdagroup.ca](http://www.kdagroup.ca) and on SEDAR at [www.sedar.com](http://www.sedar.com).

### **About ZoomMed**

ZoomMed builds and operates ZoomMed's Communication Network, a clinical interoperable information exchange network between physicians and the various other stakeholders of the healthcare sector, such as pharmacists, specialists, pharmaceutical corporations and private insurers.

The cornerstone of this network is the ZRx Prescriber, an innovative Web technology application that greatly simplifies prescription writing for physicians. Since it is a stand-alone product, it can easily be integrated into any Electronic Medical Record (EMR) application.

- 30 -

### **CAUTION REGARDING FORWARD-LOOKING STATEMENTS**

*This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.*

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.*

### **INFORMATION**

Marc Lemieux  
Chief Executive Officer  
514 622-7370  
[info@groupekda.ca](mailto:info@groupekda.ca)